<p>（第一财经）5 月 18 日——中国第 12 批国家组织集中药品采购的招标将涵盖创纪录的 70 多种药品和 233 个规格。</p>
<p>这些数据由国家药品集中采购办公室于 5 月 15 日发布，基于制药公司的早期申报。实际上，这是首次采用预申报机制的集中药品采购，旨在使药品选择过程更加公开透明。</p>
<p>上海健康发展研究中心主任金春林表示，主要品种之间的竞争非常激烈。一些计划纳入的明星品种，如 Entresto（沙库巴曲缬沙坦钠片），年销售额已高达 80 亿元人民币（12 亿美元）。</p>
<p>对于企业来说，竞争压力相当大，因为集中采购对纳入的药品品种的市场趋势有很大影响。</p>
<p>根据预申报数据，抗肿瘤治疗药物、心血管药物、糖尿病药物、免疫抑制剂和抗感染药物将成为下一批集中药品采购的一部分，这些药物在医院中普遍使用。</p>
<p>5 月 1 日，上海实施了医疗保险支付改革，将医疗保险报销的上限设定为选定的集中采购价格。如果患者选择未被选中的原研药，必须全额支付超出部分，因为该市打击了高价药品在 “按比例报销” 模式下获得隐性医疗保险补贴的趋势。</p>
<p>金指出，新报销政策对实际集中采购量的影响有限，医院在报告量时可能会比较保守，但仍需履行其报告的合同量。同时，大多数患者仍会选择集中采购中选定的低价产品，除非原研药具有显著的临床价值。</p>
<p>国家医疗保障局将进一步优化集中采购规则，并采用招标、询价和综合评估等多种方式，促进企业之间的理性竞争，国家医疗保障局副局长施自海在 4 月表示。</p>
<p>编辑：Futura Costaglione</p>

国泰中证生物医药ETF

天弘国证生物医药ETF

华夏中证生物科技主题ETF

<p>中国第十二批集中药品采购将包括超过 70 个品种和 233 个规格，创下历史新高。本批次引入了预备案机制以提高透明度。像 Entresto 这样的主要药物，年销售额达到 80 亿元人民币，面临激烈竞争。新的医疗保险政策将报销限制在采购价格，影响患者选择更低价的选项。国家医疗保障局计划加强采购规则，以促进企业之间的竞争</p>

<p>(Yicai) May 18 -- China’s 12th batch of bidding for the state-organized centralized drug procurement program will cover a new record number of over 70 varieties and 233 specifications.</p>
<div class="lb-trans"><p>（第一财经）5 月 18 日——中国第 12 批国家组织集中药品采购的招标将涵盖创纪录的 70 多种药品和 233 个规格。</p>
</div><p>The figures were released by the National Organization for Drug Joint Procurement Office on May 15, and they are based on the early filings by pharmaceutical companies. In fact, this is the first batch of centralized drug procurement to feature a pre-filing mechanism, aiming to make the drug selection process more open and transparent.</p>
<div class="lb-trans"><p>这些数据由国家药品集中采购办公室于 5 月 15 日发布，基于制药公司的早期申报。实际上，这是首次采用预申报机制的集中药品采购，旨在使药品选择过程更加公开透明。</p>
</div><p>The competition among major varieties is extremely fierce, said Jin Chunlin, director of the Shanghai Health Development Research Center. Some star varieties slated for inclusion, including Entresto‌ (sacubitril valsartan sodium tablets), have recorded annual sales of up to CNY8 billion (USD1.2 billion).</p>
<div class="lb-trans"><p>上海健康发展研究中心主任金春林表示，主要品种之间的竞争非常激烈。一些计划纳入的明星品种，如 Entresto（沙库巴曲缬沙坦钠片），年销售额已高达 80 亿元人民币（12 亿美元）。</p>
</div><p>For enterprises, the competitive pressure is quite large, as the centralized procurement has a big impact on the market trend of the drug varieties included.</p>
<div class="lb-trans"><p>对于企业来说，竞争压力相当大，因为集中采购对纳入的药品品种的市场趋势有很大影响。</p>
</div><p>Anti-tumor treatments, cardiovascular drugs, diabetes medications, immunosuppressants, and anti-infective drugs will be part of the next batch of centralized drug procurement, all of which are commonly used in hospitals, according to the pre-filing data.</p>
<div class="lb-trans"><p>根据预申报数据，抗肿瘤治疗药物、心血管药物、糖尿病药物、免疫抑制剂和抗感染药物将成为下一批集中药品采购的一部分，这些药物在医院中普遍使用。</p>
</div><p>On May 1, Shanghai implemented a reform to medical insurance payment, setting the upper limit of medical insurance reimbursement at the selected centralized procurement price. If patients choose non-selected original drugs, they must pay the excess in full now, as the city cracked down on the trend where high-priced drugs received disguised medical insurance subsidies under the ‘proportional reimbursement’ model.</p>
<div class="lb-trans"><p>5 月 1 日，上海实施了医疗保险支付改革，将医疗保险报销的上限设定为选定的集中采购价格。如果患者选择未被选中的原研药，必须全额支付超出部分，因为该市打击了高价药品在 “按比例报销” 模式下获得隐性医疗保险补贴的趋势。</p>
</div><p>The new reimbursement policy has a limited impact on the actual centralized procurement volume, Jin noted, adding that hospitals may be conservative when reporting volumes, but they still need to fulfill the contracted volumes they reported. Meanwhile, most patients will still choose the lower-priced products selected in centralized procurement, unless the original drugs have significantly outstanding clinical value.</p>
<div class="lb-trans"><p>金指出，新报销政策对实际集中采购量的影响有限，医院在报告量时可能会比较保守，但仍需履行其报告的合同量。同时，大多数患者仍会选择集中采购中选定的低价产品，除非原研药具有显著的临床价值。</p>
</div><p>The National Healthcare Security Administration will further optimize the centralized procurement rules and adopt various methods, such as bidding, inquiry, and comprehensive evaluation, to promote rational competition among enterprises, Shi Zihai, deputy director of the NHSA, said in April.</p>
<div class="lb-trans"><p>国家医疗保障局将进一步优化集中采购规则，并采用招标、询价和综合评估等多种方式，促进企业之间的理性竞争，国家医疗保障局副局长施自海在 4 月表示。</p>
</div><p>Editor: Futura Costaglione</p>
<div class="lb-trans"><p>编辑：Futura Costaglione</p>
</div>

中国第十二批集中药品采购将涵盖创纪录数量的药品品种